Skip to content

All recalls FDA

FDADrugsRecalled Status: Ongoing

Imprimis NJOF, LLC recalls Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL

Class IIofficial

FDA Class II

FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.

Hazard
Presence of particulate matter - Glass like particles.
Products
  • Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL
Where it was sold

U.S Nationwide

Nationwide

Units affected
314 boxes of 6,280 pre-filled syringes
About this recall
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.